UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010977
Receipt number R000012852
Scientific Title A study on the safety and efficacy of hypofractionated radiotherapy in post-operative irradiation for breast cancer patients
Date of disclosure of the study information 2013/06/17
Last modified on 2015/12/17 23:04:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the safety and efficacy of hypofractionated radiotherapy in post-operative irradiation for breast cancer patients

Acronym

A study of hypofractionated radiotherapy for breast cancer

Scientific Title

A study on the safety and efficacy of hypofractionated radiotherapy in post-operative irradiation for breast cancer patients

Scientific Title:Acronym

A study of hypofractionated radiotherapy for breast cancer

Region

Japan Asia(except Japan)


Condition

Condition

Breast cancer

Classification by specialty

Breast surgery Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To prove that hypofractionated whole breast irradiation in breast conserving thrapy and hypofractionated post mastectomy regional radiothetapy are as safe and as effective as conventionally fractionated radiotherapy and superior in terms of convenience.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

Local recurrence-free survival rate (in radiation fields)

Key secondary outcomes

Acute adverse events (the skin, subcutaneous tissue, breast tissue, and lungs)
Late advese events (the skin, subcutaneous tissue, breast tissue, lungs, ribs and the heart)
Cosmetic outcome


Base

Study type

Interventional


Study design

Basic design

Factorial

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

For cases of post breast conserving surgery without high grade factors (age < 50, positive axillary nodes, lymphovascular invasion, or close margins)- 43.2 Gy to the whole breast in 16 fractions over 22 days for (tumor bed boosts are not performed)

Interventions/Control_2

For cases of post breast conserving surgery with positive high grade factors - 43.2 Gy to the whole breast in 16 fractions over 22 days with an additional tumor bed boost of 8.1 Gy in 3 fractions

Interventions/Control_3

For cases of post mastectomy with negative surgical margins - 43.2 Gy to the chest wall and supraclavicular region in 16 fractions over 22 days.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1. Eligibility criteria for HF-WBI
Patient who has undergone BCT and have been histopathologically confirmed to have breast cancer
The size of primary tumor is either Tis, T1 or T2
Patient who has undergone a lymph node dissection (including sentinel lymph node biopsy) and has been histopathologically confirmed to have 3 positive lymph nodes or less.
Consent of the patient for the trial obtained

2. Eligibility criteria for HF-PMRT
Patient who has undergone any type of mastectomy and have been histopathologically confirmed to have breast cancer
Patient without positive margin.
Patient who has undergone a lymph node dissection (including sentinel lymph node biopsy) and has been histopathologically confirmed to have less than 8 positive lymph nodes.
Consent of the patient for the trial obtained

Key exclusion criteria

Internal mammary lymph node metastasis.
Residual axillary lymph node or who need to irradiate axially region.
Distant metastasis.
Any active collagen disease
Active double primary cancer (except for carcinoma in situ and bilateral breast cancer)
Concurrent chemoradiotherapy
Previous chest irradiation
Pregnancy and potential pregnancy

Target sample size

400


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kumiko Karasawa

Organization

Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences

Division name

Treatment Team

Zip code


Address

4-9-1 Anagawa, Inage-ku, Chiba-city,Chiba, Japan

TEL

043-206-3306

Email

kkarasaw@nirs.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kumiko Karasawa

Organization

Research Center Hospital for Charged Particle Therapy,National Institute of Radiological Sciences

Division name

Treatment Team

Zip code


Address

4-9-1 Anagawa, Inage-ku, Chiba-city,Chiba, Japan

TEL

043-206-3306

Homepage URL


Email

kkarasaw@nirs.go.jp


Sponsor or person

Institute

National Institute of Radiological Sciences

Institute

Department

Personal name



Funding Source

Organization

National Institute of Radiological Sciences

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

13-001

Org. issuing International ID_1

National Institute of Radiological Sciences

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

デルタ病院(バングラデシュ)
蘇州大学附属第一医院(中国)
複旦大学上海がんセンター(中国)
インドネシア大学チプト マングンクスモ病院(インドネシア)
ソエトモ総合病院診療センター(インドネシア)
放射線医学総合研究所重粒子医科学センター病院(千葉県)
埼玉医科大学国際医療センター(埼玉県)
弘前大学附属病院(青森県)
群馬大学附属病院(群馬県)
セメイ国立医科大学(カザフスタン)
韓国放射線医科学研究所(韓国)
韓国がんセンター病院(韓国)
サラワク総合病院(マレーシア)
モンゴル国立がんセンター(モンゴル)
聖ルーク医療センター(フィリピン)
フィリピン ホセ・レイエス記念医療センター(フィリピン)
マヒドール大学シリラート病院(タイ)
ホーチミン市腫瘍病院(ベトナム)
国立がんセンター(ベトナム)


Other administrative information

Date of disclosure of the study information

2013 Year 06 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2013 Year 05 Month 17 Day

Date of IRB


Anticipated trial start date

2013 Year 05 Month 17 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 06 Month 17 Day

Last modified on

2015 Year 12 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012852


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name